GeNeuro SA Postpones Publication of June 30, 2025 Half-Yearly Financial Report
Geneva, Switzerland, 15 October 2025 – 6:00 pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces the postponement of its June 30, 2025 half-yearly results and half-yearly financial report. This decision is in line with the postponement of the annual results for the […]